Literature DB >> 2029694

Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.

A E Taylor1, A E Lang, J A Saint-Cyr, D E Riley, R Ranawaya.   

Abstract

Studies utilizing single doses of scopolamine have suggested a role for the cholinergic system in memory. Results are consistent in identifying a selective effect on the early encoding stage of information processing. In terms of long-term administration of anticholinergics, patients with Parkinson's disease often display memory deficits. However, underlying pathology within the forebrain cholinergic system complicates the study of treatment effects in this disorder. We therefore assessed multiple memory routines in 20 cognitively intact patients with dystonia where no such pathology has been identified. Patients were tested before and after 2-4 months of 15-74 mg of trihexyphenidyl daily. Twelve tolerated this regime. Compared to control subjects, matched for age and I.Q., only tests with a single presentation of the material to be remembered were affected at follow-up. The speed of information processing was also significantly reduced. Age was strongly related to memory performance in the patient group alone and interacted with dose and duration of treatment. Results suggest that drug-induced slowing of mentation was responsible for impaired encoding, particularly in older patients. These findings affect treatment strategies, especially now that injections of botulinum toxin have proved to be highly effective for certain forms of focal dystonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029694     DOI: 10.1097/00002826-199102000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  12 in total

Review 1.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 3.  Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits.

Authors:  Samuel S Pappas; Daniel K Leventhal; Roger L Albin; William T Dauer
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

Review 4.  Nonmotor manifestations of dystonia: a systematic review.

Authors:  Daniel J Kuyper; Veronica Parra; Shanae Aerts; Michael S Okun; Benzi M Kluger
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

Review 5.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 6.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

7.  Dystonia treatment: Patterns of medication use in an international cohort.

Authors:  Sarah Pirio Richardson; Ashley R Wegele; Betty Skipper; Amanda Deligtisch; H A Jinnah
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

8.  Botulinum toxin type A versus anticholinergics for cervical dystonia.

Authors:  Filipe B Rodrigues; Gonçalo S Duarte; Mafalda Castelão; Raquel E Marques; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

9.  Pallidal stimulation for primary generalised dystonia: effect on cognition, mood and quality of life.

Authors:  Marjan Jahanshahi; Mariam Torkamani; Mazda Beigi; Leonora Wilkinson; Donna Page; Laura Madeley; Kailash Bhatia; Marwan Hariz; Ludvic Zrinzo; Patricia Limousin; Diane Ruge; Stephen Tisch
Journal:  J Neurol       Date:  2013-11-01       Impact factor: 4.849

10.  Screening for Cognitive Impairments in Primary Blepharospasm.

Authors:  Jing Yang; Wei Song; Qianqian Wei; Ruwei Ou; Bei Cao; Wanglin Liu; Na Shao; Hui-Fang Shang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.